Melanie Mead
Women's Health · Tulsa, OKNPI 1942257266
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2021 at $698 and has fallen 55.5% since, to $311 in 2025.
Across 141 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$783
- Astellas Pharma US Inc$234
- Sumitomo Pharma America, Inc.$226
- Mayne Pharma Commercial LLC$205
- Organon$166
- Myovant Sciences Inc.$140
- plus $950 from 18 others
What the payments were for
- Food & beverage$2,705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $783 |
| Astellas Pharma US Inc | 9 | $234 |
| Sumitomo Pharma America, Inc. | 9 | $226 |
| Mayne Pharma Commercial LLC | 5 | $205 |
| Organon | 8 | $166 |
| Myovant Sciences Inc. | 7 | $140 |
| Therapeuticsmd, Inc. | 7 | $123 |
| Pfizer | 7 | $118 |
| Exeltis, USA Inc. | 6 | $113 |
| Millicent US Inc | 5 | $102 |
| Hologic Sales And Service, LLC | 5 | $92 |
| Bayer | 3 | $62 |
| Scynexis, Inc. | 3 | $47 |
| Evofem Biosciences, Inc. | 3 | $45 |
| Minerva Surgical, Inc | 1 | $40 |
| Sage Therapeutics, LLC | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Vertex | 1 | $29 |
| Avion Pharmaceuticals | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Convatec Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIJUVA$117
How this compares
$2,705 in reported general payments places this provider in the 85th percentile of 62 women's health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $15,110 |
| Estradiol | 256 | $9,807 |
| PremarinEstrogens, Conjugated | 14 | $7,565 |
| DuaveeEstrogens,conj/Bazedoxifene | 14 | $2,658 |
| ProgesteroneProgesterone, Micronized | 108 | $2,479 |
| Raloxifene Hcl | 25 | $2,037 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 15 | $1,904 |
| Estradiol (Once Weekly)Estradiol | 18 | $1,687 |
| Metronidazole | 87 | $1,296 |
| Halobetasol Propionate | 34 | $1,219 |
| YuvafemEstradiol | 14 | $872 |
| DottiEstradiol | 13 | $635 |
| ValacyclovirValacyclovir Hcl | 19 | $583 |
| Medroxyprogesterone Acetate | 48 | $422 |
| LuteraLevonorgestrel/Ethin.Estradiol | 14 | $327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $234 | $15,11011 claims |
| PfizerPremarin, Duavee | $118 | $10,22328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 women's health providers in Oklahoma.
Other women's health in Tulsa
- April ZumwaltTulsa$4K
- Kerri VandiverTulsa$3K
- Alexandra MortonTulsa$3K
- Melissa WilsonTulsa$2K
- Julie StylesTulsa$915
- Kelley ScottTulsa$717
- Leslie KingTulsa$360
- Sherri FisherTulsa$133
- Kelly StemmTulsa$63
- Delana GreggTulsa$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.